Integrum's CEO Rickard Brånemark holds the keynote lecture at ISPO 2023 in Germany
Mölndal, Sweden, May 09, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the company's CEO Rickard Brånemark will hold the keynote lecture on Bionic Limb Reconstructions, at the International Society for Prosthetics and Orthotics, ISPO 2023 in Hanover, Germany.
The meeting is taking place between May 11-12 at Lower Saxony Center for Biomedical Engineering, Implant Research and Development (NIFE) and Hanover Medical School in Hanover. The keynote lecture will be held on Thursday, May 11 at 19.30. Integrum is also attending the conference with a booth to welcome healthcare professionals and other interested visitors.
"The ISPO meeting is an important forum for physicians, prosthetists, and scientists and provides an excellent opportunity to discuss new findings with the leading names in the field of osseointegration. It is also an excellent opportunity for us to exchange knowledge and spread information to healthcare personnel about our innovative and unique implant systems", comments Professor Rickard Brånemark, CEO of Integrum.
In connection with the conference, Integrum is organizing an instructional course for prosthetists on the OPRA™ Implant System, including Rehabilitation and prosthetic fitting for transhumeral patients and prosthetic fitting with the Axor™ II for transfemoral patients. The course will take place on Wednesday, May 10, 13-16 at Nife Stadtfelddamm 34, in Hanover.
Integrum's OPRA™ Implant System is a bone-anchored system based on osseointegration. As the prostheses are directly attached to the bone, the use of a socket is avoided, leading to fewer complications and better quality of life for the patient.
For more information please contact:
Rickard Brånemark, CEO.
Phone: +46 70 846 10 61
E-mail: rickard.branemark@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.